GO
| HSI1 | 25,630.54 | -224.06 | 118.97B |
| HSCEI1 | 8,913.68 | -77.34 | 46.35B |
| Back Zoom + Zoom - Block Traded | |
|
2025-12-31 09:55:39 RIBOLIFE-B (06938.HK), a biopharmaceutical company with a focus on siRNA therapeutics, has announced details of its IPO in Hong Kong. The company plans to globally issue 27.4874 million H-shares, with around 10% for Hong Kong public offering and about 90% for international placement. With an offer price of HKD57.97 per share, the IPO aims to raise a maximum of around HKD1.593 billion. The entry fee for a board lot of 200 shares will be about HKD11,710.93. The IPO period starts today (December 31) and ends at noon next Tuesday (January 6), with the listing expected next Friday (January 9). ~ AAStocks Financial News Web Site: www.aastocks.com | |